We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Berlex, a U.S. affiliate of Bayer Schering Pharma, announced that the FDA has approved a new indication for Yaz (3 mg drospirenone/20 micrograms ethinyl estradiol) to treat moderate acne vulgaris in women who desire an oral contraceptive for birth control.
GlaxoSmithKline (GSK) announced that its new H5N1 split-antigen prepandemic influenza vaccine has been accepted for review by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA).
Spectrum Pharmaceuticals announced that the first patient has been dosed in the company's Phase IIb U.S. study of ozarelix in patients with benign prostate hypertrophy (BPH).
Approximately half of patients with advanced small-cell lung cancer responded to Introgen Therapeutics' INGN 225 molecular cancer vaccine in combination with subsequent chemotherapy.
Shin Poong Pharm and the Medicines for Malaria Venture (MMV) have begun recruiting patients to participate in a pivotal clinical trial of Pyramax (pyronaridine artesunate), a new artemisinin-based combination treatment for malaria.
Amgen has sent a letter informing healthcare professionals of the results of a large, multicenter, randomized, placebo-controlled study showing that Aranesp was ineffective in reducing red blood cell transfusions in cancer patients who have anemia that is not due to concurrent chemotherapy.